Oncolytics (ONCY) Biotech continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep’s potential in hard-to-treat cancers. Oncolytics highlights two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new efficacy and safety data at the 2025 American Society of Clinical Oncology, ASCO, Gastrointestinal Cancers Symposium in late January. German Regulatory Agency Gives Green Light for Pancreatic Cancer Study to Continue as Planned; ASCO GI 2025 Data Confirms Pelareorep’s Potential in Pancreatic and Anal Cancers
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics provides progress update for pelareorep in pancreatic and anal cancer
- Oncolytics Biotech Advances Cancer Treatment Pipeline with Key 2025 Developments
- Oncolytics making progress in 2025 with regulatory, clinical advancements
- Oncolytics Biotech Receives Nasdaq Notification for Bid Price Deficiency
- Oncolytics receives noncompliance notification from Nasdaq